All In Biotech

Drug Trial Radar · NCT07281079

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared With Placebo in Pediatric Participants With Phelan-McDermid Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Oct 31, 2027

Study completion Nov 15, 2027

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.

Conditions

  • Phelan-McDermid Syndrome

Interventions

  • NNZ-2591Drug

    The study drug will be administered twice daily orally.

  • PlaceboDrug

    The study drug will be administered twice daily orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score.Time frame: Week 13
  2. Efficacy of NNZ-2591 compared with placebo as measured by the change from baseline in the Vineland Adaptive Behavior Scales-3, Interview version (Vineland-3) receptive communication subdomain raw score.Time frame: Week 13

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Neuren PMS-301 Site #116

    Birmingham, Alabama · Recruiting

  • Neuren PMS-301 Site#122

    Glendale, California · Recruiting

  • Neuren PMS-301 Site #112

    Palo Alto, California · Recruiting

  • Neuren PMS-301 Site#103

    San Diego, California · Recruiting

  • Neuren PMS-301 Site#111

    San Rafael, California · Recruiting

  • Neuren PMS-301 Site #107

    Washington D.C., District of Columbia · Recruiting

  • Neuren PMS-301 Site #105

    Atlanta, Georgia · Recruiting

  • Neuren PMS-301 Site#102

    Chicago, Illinois · Recruiting

  • Neuren PMS-301 Site#109

    Chevy Chase, Maryland · Recruiting

  • Neuren PMS-301 Site#106

    Brookline, Massachusetts · Recruiting

  • Neuren PMS-301 Site#104

    Lexington, Massachusetts · Recruiting

  • Neuren PMS-301 Site #117

    Ann Arbor, Michigan · Recruiting

  • Neuren PMS-301 Site#101

    New York, New York · Recruiting

  • Neuren PMS-301 Site#108

    Cincinnati, Ohio · Recruiting

  • Neuren PMS-301 Site#110

    Columbus, Ohio · Recruiting

  • Neuren PMS-301 Site#115

    Houston, Texas · Recruiting

  • Neuren PMS-301 Site #113

    Charlottesville, Virginia · Recruiting

  • Neuren PMS-301 Site#201

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.